Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Current frontline treatment for WM

Jorge Castillo and Ramon Garcia-Sanz • 14 Sep 2019
IMW 2019
Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine BTK inhibitors Carfilzomib Cyclophosphamide Dexamethasone Ibrutinib Rituximab

Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the current frontline treatments for Waldenström’s Macroglobulinemia (WM), from the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jorge Castillo

Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo et al. • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo et al. • 8 Dec 2025
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
3:13
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
Jorge Castillo et al. • 7 Dec 2024
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
2:25
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
Jorge Castillo et al. • 7 Dec 2024

More from Ramon Garcia-Sanz

The diagnosis and characterization of Waldenström's macroglobulinemia
1:48
The diagnosis and characterization of Waldenström's macroglobulinemia
Jorge Castillo et al. • 16 Jun 2024
Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia
1:29
Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia
Jorge Castillo et al. • 16 Jun 2024
Results from a study on the combination of sonrotoclax and zanubrutinib in R/R MCL
1:38
Results from a study on the combination of sonrotoclax and zanubrutinib in R/R MCL
Jorge Castillo et al. • 16 Jun 2024
An overview of the management of patients with R/R Waldenström’s macroglobulinemia
2:09
An overview of the management of patients with R/R Waldenström’s macroglobulinemia
Jorge Castillo et al. • 16 Jun 2024

Related Videos

Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
2:24
Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis
Jorge Castillo et al. • 10 Dec 2025
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
1:13
Two-year follow-up from ZUMA-2: safety and efficacy of brexu-cel in R/R MCL
Jorge Castillo et al. • 10 Dec 2025
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
5:31
A novel cell model of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Jorge Castillo et al. • 10 Dec 2025
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Jorge Castillo et al. • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals